glp-1 agonist moa Glucagon-like peptide-1 receptor: mechanisms and advances in therapy Cardiovascular Protection with a Long-Acting

Not for use during pregnancy or nursing without guidance from your provider

These drugs effectively lower blood glucose levels and provide cardiovascular and renal benefits, making them a preferred treatment option in diabetes care

Although, in the last 10 years, the use of GLP-1 RAs, especially semaglutide and liraglutide, has increased, its clinical implications and how it affects metabolic parameters have yet to be fully consolidated

In late April 2025, the FDA issued a key update regarding the use of compounded GLP-1 receptor agonists like semaglutide and tirzepatide

While natural approaches to raising GLP-1 are not as potent as medications, they provide a drug-free approach to weight loss and healthy eating.